REVERE
Live / Applied — Second extension granted (statement of use) (as of 12 Mar 2026)
What this means for you
Not registered yet, but its 28 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97861964
- Mark type
- Stylized text
- Filed
- 28 Mar 2023
- Published for opposition
- 14 Jan 2025
- Attorney of record
- John V. Hobgood, Esquire
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment oncological diseases and conditions, kidney diseases and conditions, inflammatory diseases and conditions and central nervous system diseases and conditions
Owner
- Revere Pharmaceuticals, Inc., Arlington, MA, US
- Revere Pharmaceuticals, Inc., Arlington, MA, US
Prosecution history
- 13 Mar 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 12 Mar 2026 — SOU EXTENSION 2 GRANTED
- 11 Mar 2026 — SOU EXTENSION 2 FILED
- 11 Mar 2026 — SOU TEAS EXTENSION RECEIVED
- 12 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 11 Sept 2025 — SOU EXTENSION 1 GRANTED
- 11 Sept 2025 — SOU EXTENSION 1 FILED
- 11 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 11 Mar 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 14 Jan 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 14 Jan 2025 — PUBLISHED FOR OPPOSITION
- 08 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 19 Dec 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 13 Mar 2024 — CORRESPONDENCE E-MAILED
- 13 Mar 2024 — SUSPENSION LETTER WRITTEN